HRMY - NASDAQ
Harmony Biosciences Holdings, Inc.
$32.10
+0.91%Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
At a Glance
Live SnapshotHarmony Biosciences Holdings, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $554.0M | $881.3M | $1.4B | $2.2B | $3.5B | $5.6B | $9.0B | $14.3B | $22.7B | $36.2B |
| Maintenance CapEx | -$98.6K | -$156.9K | -$249.7K | -$397.2K | -$631.9K | -$1.0M | -$1.6M | -$2.5M | -$4.0M | -$6.4M |
| Owner Earnings | $553.9M | $881.2M | $1.4B | $2.2B | $3.5B | $5.6B | $9.0B | $14.3B | $22.7B | $36.2B |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | $512.8M | $755.5M | $1.1B | $1.6B | $2.4B | $3.6B | $5.2B | $7.7B | $11.4B | $16.8B |
Related Guides
Continue your HRMY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.